Head-to-head · WeighScore
GoodRx vs NuBloom
The verdict
GoodRx takes it — 69.6/100 to 69/100, but only just.
GoodRx grades higher on WeighScore, our editorial score across cost value, dose & formulation, clinical oversight, labs & monitoring, fulfillment and contract terms. GoodRx (NASDAQ: GDRX) is the largest US prescription savings platform. NuBloom is close behind and may still be the better fit — see the factor split below.
We may earn a commission if you start care through some of these links, at no extra cost to you. It never moves the WeighScore, which is the weighted average of the six factors shown for every provider, and what we write about a provider is the same either way. See our disclosure.
Factor by factor
The same six graded dimensions, side by side. See the methodology.
The numbers
| Metric | GoodRx | NuBloom |
|---|---|---|
| WeighScore | 69.6/100 | 69/100 |
| Grade | C | C |
| Scorecard rank | #122 | #137 |
| Semaglutide | Not disclosed | $149/mo (2.4 mg dose, compounded) |
| Tirzepatide | $299/mo (brand Zepbound) | $279/mo (15 mg dose, compounded) |
| Coverage | All 50 states | 49 states |
| Brand-name access | Yes | Compounded only |
| Oral / sublingual | Injection only | Injection only |
Graded #122 · C
Strengths
- $149/month self-pay for brand-name Foundayo (orforglipron) — matches the lowest cash price at launch, far below typical retail
- $299/month self-pay for Zepbound KwikPen — well under Lilly's typical cash list price
- Honored at 70,000+ US pharmacies — the largest retail redemption network of any GLP-1 channel we cover
- No membership fee — bring your own prescription and present the discount card at the pharmacy counter
- Brand-name FDA-approved medication, not compounded
Where it loses points
- Requires a valid prescription — GoodRx is a discount card, not a prescriber; you still need a clinician to write the script
- Self-pay only — does not apply toward insurance benefits or deductibles
- Headline price applies to the lowest Foundayo dose; higher doses may cost more
- No compounded GLP-1 options — not the channel for compounded semaglutide or tirzepatide
- Pricing can change as Lilly's manufacturer coupon program evolves
Graded #137 · C
Strengths
- Transparent, openly published pricing: compounded semaglutide $149/mo and tirzepatide $279/mo as flexible month-to-month subscriptions
- Founded and medically led by a named physician (Dr. Marianne Pinkston Mueller, family/integrative medicine, 25+ years)
- Whole-person model pairs GLP-1s with hormone, gut-health and longevity care plus in-depth lab testing
- State coverage published openly: 49 states listed on the site (all except Mississippi)
- Optional 90-day 1:1 coaching program with weekly meetings and unlimited text support ($599/mo)
Where it loses points
- Compounding pharmacy partners are not named anywhere on the site — a transparency gap
- NuBloom's own LegitScript/PCAB status is not displayed; only its telehealth partner is certified
- Compounded medications are not FDA-approved; one FAQ loosely calls them 'FDA-approved,' contradicting the product pages
- All sales are final and medical consult fees are non-refundable; no returns on prescription products
- Disputes go to binding individual arbitration; the Terms' governing-law state is left as an unfilled '[STATE]' placeholder
Also worth a look
Neither is our top-graded pick — CoreAge Rx leads the scorecard
Across all 499 providers, CoreAge Rx grades highest at 91.8/100 (A−). Top of the scorecard: flat transparent pricing, both molecules, nationwide — no teaser-rate games.
Pricing/verification reflect each provider's public disclosures at last grading; the WeighScore is our editorial judgment per the methodology. Prices change — confirm on each provider's site. Not medical advice; see our disclosure.